MYCN


Also found in: Acronyms, Encyclopedia.

MYCN

A gene on chromosome 2p24.3 that encodes a DNA-binding transcription factor.
 
Molecular pathology
MYCN mutation causes Feingold syndrome; MYCN is amplified in various tumours, especially in neuroblastomas.
References in periodicals archive ?
MYCN oncoprotein targets and their therapeutic potential.
Lesne et al., "Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism," Oncotarget, vol.
Targeting MYCN IRES in MYCN-amplified neuroblastoma with miR-375 inhibits tumor growth and sensitizes tumor cells to radiation.
A key finding was that the researchers could block cancer cell self-renewal in the MYCN cells by blocking heme synthesis.
Honna et al., "Successful tandem (autologous-cord blood) SCT in advanced neuroblastomas with highly amplified MYCN," Bone Marrow Transplantation, vol.
Cell line Site Stage Patient age Phase of therapy CHLA-15 Tumor 4 >1 DX CHLA-20 Tumor 4 1.5 PD-Ind CHLA-90 BM 4 8.5 PD-Auto-BMT LAN-5 BM Unknown 0.4 Unknown NUB-7 LN 4s/4 0.7 Unknown SH-SY5Y BM 4 4 PD-Ind BE(2)C BM 4 2.2 PD-Ind SK-N-BE(2) BM 4 2.2 PD-Ind Cell line MYCN amp p53 mutant CHLA-15 N WT CHLA-20 N WT CHLA-90 N Mut LAN-5 A WT NUB-7 A WT SH-SY5Y N WT BE(2)C A Mut SK-N-BE(2) A Mut BM = bone marrow; B = bone; L = liver; P = pulmonary; LN = lymph node; DX = at diagnosis; PD-Ind = progressive disease on induction chemotherapy; BMT = bone marrow transplantation; PD-Auto-BMT = relapsed after myeloablative chemo-radiotherapy followed by bone marrow transplantation; WT = wild type; Mut = mutant; N = nonamplified; A = amplified.
Vider et al., "MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas," The FASEB Journal, vol.
The predicted targets of miR-145 were oncogenes myc myelocytomatosis viral-related oncogene (MYCN), FOS, and yamaguchi sarcoma oncogene (YES); cell-cycle promoters such as cyclins D2 and L1; and mitogen-activated protein kinase (MAPK) transduction proteins such as MAP3K3 and MAP4K4 [40].
Moreover, the oncogene MYCN, a member of the MYC family of basic helix-loop-helix transcription factors, has been described to bind the AURKA promoter either alone or in complex with the DNA methyl binding protein MeCP2 in the neuroblastoma derived cell line Kelly [14].
Clinically relevant pediatric factors that influence survival in children include stage, age, histology, tumor grade, MYCN oncogene status, chromosome 11q status, and DNA ploidy.